Lyka Labs Secures Indian Patent for Pregabalin Gel 8%: A Novel Topical Solution for Diabetic Neuropathic Pain

Lyka Labs Limited has been granted an Indian Patent for its proprietary product, Pregabalin Gel 8%. This topical formulation, designed for the effective management of diabetic neuropathic pain, received regulatory approval in October 2024 for manufacturing and marketing in India. The product was officially launched in December 2024 by Torrent Pharmaceuticals, Intas Pharmaceuticals, and Zuventus Healthcare under a P2P (Product-to-Product) license from Lyka Labs. The gel formulation offers localized delivery of pregabalin directly at the site of pain, potentially minimizing systemic exposure and related side effects. Lyka Labs has conducted clinical studies supporting the efficacy, safety, and patient convenience of Pregabalin Gel 8%. This patent strengthens Lyka Labs' intellectual property portfolio and reaffirms its vision to be at the forefront of innovative pharmaceutical solutions.